These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11389126)

  • 61. National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents.
    Liebowitz LD; Slabbert M; Huisamen A
    J Clin Pathol; 2003 May; 56(5):344-7. PubMed ID: 12719453
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Perspectives of use of moxifloxacin for treatment of urogenital infections].
    Sidorenko SV
    Antibiot Khimioter; 2002; 47(1):36-42. PubMed ID: 12077939
    [No Abstract]   [Full Text] [Related]  

  • 63. [Pharmacodynamic assessment of antibiotic sensitivity of Streptococcus pneumoniae].
    Soriano F
    Med Clin (Barc); 1999 Jun; 113(3):103-8. PubMed ID: 10464745
    [No Abstract]   [Full Text] [Related]  

  • 64. In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections.
    Ozdek SC; Miller D; Flynn PM; Flynn HW
    Ocul Immunol Inflamm; 2006 Dec; 14(6):347-51. PubMed ID: 17162605
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Emerging and drug-resistant infectious diseases--penicillin resistant Streptococcus pneumoniae infections].
    Kaku M
    Nihon Naika Gakkai Zasshi; 1997 Nov; 86(11):2069-74. PubMed ID: 9480312
    [No Abstract]   [Full Text] [Related]  

  • 66. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
    Saravolatz LD; Leggett J
    Clin Infect Dis; 2003 Nov; 37(9):1210-5. PubMed ID: 14557966
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Concurrent use of selected agents with moxifloxacin: an examination of labeling compliance within 1 year of marketing.
    Brinker A; Staffa J
    Arch Intern Med; 2002 Sep; 162(17):2011-2. PubMed ID: 12230426
    [No Abstract]   [Full Text] [Related]  

  • 68. The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy.
    Burka JM; Bower KS; Vanroekel RC; Stutzman RD; Kuzmowych CP; Howard RS
    Am J Ophthalmol; 2005 Jul; 140(1):83-7. PubMed ID: 15953577
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.
    Blondeau JM; Zhao X; Hansen G; Drlica K
    Antimicrob Agents Chemother; 2001 Feb; 45(2):433-8. PubMed ID: 11158737
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
    Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC
    J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.
    Boos M; Mayer S; Fischer A; Köhrer K; Scheuring S; Heisig P; Verhoef J; Fluit AC; Schmitz FJ
    Antimicrob Agents Chemother; 2001 Mar; 45(3):938-42. PubMed ID: 11181385
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Streptococcus pneumoniae resistance to fluoroquinolones.
    Wise R; Brenwald N; Gill M; Fraise A
    Lancet; 1996 Dec; 348(9042):1660. PubMed ID: 8962006
    [No Abstract]   [Full Text] [Related]  

  • 73. Moxifloxacin for community-acquired pneumonia.
    Rijnders BJ
    Antimicrob Agents Chemother; 2003 Jan; 47(1):444; author reply 444-5. PubMed ID: 12499236
    [No Abstract]   [Full Text] [Related]  

  • 74. Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features.
    Blondeau JM; Hansen GT
    Expert Opin Pharmacother; 2001 Feb; 2(2):317-35. PubMed ID: 11336589
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of the Etest with a conventional agar dilution method in evaluating the in vitro activity of moxifloxacin.
    Andrews JM; Wise R
    J Antimicrob Chemother; 2000 Feb; 45(2):257-8. PubMed ID: 10660513
    [No Abstract]   [Full Text] [Related]  

  • 76. Penetration of moxifloxacin into peripheral compartments in humans.
    Müller M; Stass H; Brunner M; Möller JG; Lackner E; Eichler HG
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2345-9. PubMed ID: 10508004
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Beau's lines in a patient treated with moxifloxacin for anaerobic pulmonary infection.
    Burkhardt O; Allewelt M; Pletz MW; Welte T; Lode H
    Scand J Infect Dis; 2003; 35(8):516-8. PubMed ID: 14514159
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Enantiomeric separation of a moxifloxacin intermediate by chiral liquid chromatography using cellulose based stationary phases.
    Radhakrishna T; Rao DS; Vyas K; Reddy GO
    J Pharm Biomed Anal; 2000 May; 22(4):691-7. PubMed ID: 10768360
    [No Abstract]   [Full Text] [Related]  

  • 79. Ciprofloxacin vs. the pneumococcus.
    Karcic AA; Khan FA
    Chest; 2000 Oct; 118(4):1226-7. PubMed ID: 11035706
    [No Abstract]   [Full Text] [Related]  

  • 80. Effects of moxifloxacin on neutrophil phagocytosis, burst production, and killing as determined by a whole-blood cytofluorometric method.
    Fischer S; Adam D
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2668-9. PubMed ID: 11523529
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.